The Genomic Landscape of Breast Cancer in Young and Older Women

IF 2.9 3区 医学 Q2 ONCOLOGY Clinical breast cancer Pub Date : 2024-07-30 DOI:10.1016/j.clbc.2024.07.008
Arielle L. Heeke , Wei Sha , Rebecca Feldman , Julie Fisher , Lejla Hadzikadic-Gusic , James T. Symanowski , Richard L. White Jr , Antoinette R. Tan
{"title":"The Genomic Landscape of Breast Cancer in Young and Older Women","authors":"Arielle L. Heeke ,&nbsp;Wei Sha ,&nbsp;Rebecca Feldman ,&nbsp;Julie Fisher ,&nbsp;Lejla Hadzikadic-Gusic ,&nbsp;James T. Symanowski ,&nbsp;Richard L. White Jr ,&nbsp;Antoinette R. Tan","doi":"10.1016/j.clbc.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Young women with breast cancer (YWBC; ≤40 years) often have a poorer prognosis than older women with breast cancer (OWBC; ≥65 years). We explored molecular features of tumors from YWBC and OWBC to identify a biologic connection for these patterns.</p></div><div><h3>Materials and Methods</h3><p>We retrospectively analyzed the molecular profiles of 1879 breast tumors. Testing included immunohistochemistry (IHC), <em>in situ</em> hybridization (ISH), and next-generation sequencing. Statistical analyses included Pearson's chi<sup>2</sup> test for comparisons, with significance defined as FDR (false discovery rate)-<em>P</em> &lt; .05.</p></div><div><h3>Results</h3><p><em>TP53</em> and <em>BRCA1</em> somatic mutations were more common in YWBC tumors than in OWBC tumors (53%, 42%; <em>P</em> = .0001, FDR<em>-P</em> = .0025 and 7%, 2%; <em>P</em> = .0001, FDR<em>-P</em> = .0025; respectively). Conversely, OWBC tumors had higher androgen receptor expression (55%, 45%; <em>P</em> = .0002, FDR<em>-P</em> = .0025) higher PD-L1 expression detected by IHC (8%, 5%; <em>P</em> = .0476, FDR<em>-P</em> = .2754), and more frequent <em>PIK3CA</em> mutations (33%, 17%; <em>P</em> = &lt; .0001, FDR<em>-P</em> = &lt; .0001). Among HR+/HER2- samples, YWBC had more gene amplifications in FGF3 (27%, 10%; <em>P</em> = .0353, FDR<em>-P</em> = .2462), FGF4 (27%, 9%; <em>P</em> = .0218, FDR<em>-P</em> = .1668), FGF19 (30%, 12%; <em>P</em> = .034, FDR<em>-P</em> = .2462) and CCND1 (37%, 18%; <em>P</em> = .0344, FDR<em>-P</em> = .2462) than OWBC.</p></div><div><h3>Conclusions</h3><p>Our data suggest distinct molecular aberrations exist between YWBC and OWBC. Exploiting these molecular changes could refine our treatment strategies in YWBC and OWBC.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"24 7","pages":"Pages 630-638.e3"},"PeriodicalIF":2.9000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1526820924002064","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Young women with breast cancer (YWBC; ≤40 years) often have a poorer prognosis than older women with breast cancer (OWBC; ≥65 years). We explored molecular features of tumors from YWBC and OWBC to identify a biologic connection for these patterns.

Materials and Methods

We retrospectively analyzed the molecular profiles of 1879 breast tumors. Testing included immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing. Statistical analyses included Pearson's chi2 test for comparisons, with significance defined as FDR (false discovery rate)-P < .05.

Results

TP53 and BRCA1 somatic mutations were more common in YWBC tumors than in OWBC tumors (53%, 42%; P = .0001, FDR-P = .0025 and 7%, 2%; P = .0001, FDR-P = .0025; respectively). Conversely, OWBC tumors had higher androgen receptor expression (55%, 45%; P = .0002, FDR-P = .0025) higher PD-L1 expression detected by IHC (8%, 5%; P = .0476, FDR-P = .2754), and more frequent PIK3CA mutations (33%, 17%; P = < .0001, FDR-P = < .0001). Among HR+/HER2- samples, YWBC had more gene amplifications in FGF3 (27%, 10%; P = .0353, FDR-P = .2462), FGF4 (27%, 9%; P = .0218, FDR-P = .1668), FGF19 (30%, 12%; P = .034, FDR-P = .2462) and CCND1 (37%, 18%; P = .0344, FDR-P = .2462) than OWBC.

Conclusions

Our data suggest distinct molecular aberrations exist between YWBC and OWBC. Exploiting these molecular changes could refine our treatment strategies in YWBC and OWBC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
年轻女性和老年女性的乳腺癌基因组图谱。
背景:年轻女性乳腺癌患者(YWBC;≤40 岁)的预后往往比老年女性乳腺癌患者(OWBC;≥65 岁)差。我们探讨了YWBC和OWBC肿瘤的分子特征,以确定这些模式的生物学联系:我们回顾性分析了 1879 例乳腺肿瘤的分子特征。检测包括免疫组化(IHC)、原位杂交(ISH)和新一代测序。统计分析包括Pearson's chi2比较检验,显著性定义为FDR(错误发现率)-P < .05:TP53和BRCA1体细胞突变在YWBC肿瘤中比在OWBC肿瘤中更常见(分别为53%、42%;P = .0001,FDR-P = .0025和7%、2%;P = .0001,FDR-P = .0025;)。相反,OWBC肿瘤的雄激素受体表达更高(55%,45%;P = .0002,FDR-P = .0025),IHC检测到的PD-L1表达更高(8%,5%;P = .0476,FDR-P = .2754),PIK3CA突变更频繁(33%,17%;P = < .0001,FDR-P = < .0001)。在HR+/HER2-样本中,YWBC比OWBC有更多的FGF3(27%,10%;P = .0353,FDR-P = .2462)、FGF4(27%,9%;P = .0218,FDR-P = .1668)、FGF19(30%,12%;P = .034,FDR-P = .2462)和CCND1(37%,18%;P = .0344,FDR-P = .2462)基因扩增:我们的数据表明,YWBC 和 OWBC 之间存在不同的分子畸变。结论:我们的数据表明,YWBC 和 OWBC 之间存在不同的分子畸变,利用这些分子变化可以完善我们对 YWBC 和 OWBC 的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical breast cancer
Clinical breast cancer 医学-肿瘤学
CiteScore
5.40
自引率
3.20%
发文量
174
审稿时长
48 days
期刊介绍: Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
期刊最新文献
Editorial Board Table of Contents Clinical and Imaging Features Associated With Malignant Focal Nonmass Enhancement on Breast MRI. Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1